New cancer drug tested in japanese patients – early results uncertain

NCT ID NCT04674748

Terminated Disease control Sponsor: Incyte Biosciences Japan GK Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tested the drug INCB086550 in 3 Japanese patients with advanced solid tumors that had stopped responding to other treatments. The main goal was to check safety and find the right dose. The study was terminated early, so we have limited information on how well it worked.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: INCB086550
What this could lead to: If successful, this could point toward a new treatment option for advanced solid tumors in Japanese patients.
What could go wrong: This is a very early, small Phase 1 trial (only 3 participants) that was terminated, so results are limited. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm Neoplasm Metastasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

National Cancer Center Hospital

Tokyo, 104-0045, Japan
National Cancer Center Hospital - East

Chiba, 277-8577, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.